Hosted on MSN3d
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
STAT10d
Sales of GSK’s RSV vaccine down dramatically from last year
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
FiercePharma11d
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
BioPharma Dive11d
GSK vaccine sales sink on lower demand for RSV, shingles shots
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
New RSV Vaccine Distribution: Who’s at the Top of the List?
With RSV season approachgin, there are more options for those most susceptible to RSV, including a new vaccine and updated ...
Everything You Need To Know About RSV This Fall
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
GSK shares fall as vaccine demand disappoints
In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.
GlobalData on MSN4d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...